Human Genome Sciences in the crosshairs

GSK lines up nominees for company’s board in hostile takeover move, and some say Celgene may enter as a rival

Jeffrey Bouley
As the hostile takeover bid by GlaxoSmithKline PLC (GSK)against Human Genome Sciences Inc. (HGS) continues, GSK has now reportedly linedup 12 candidates it may propose to have replace all of those members who are alreadyon the HGS board of directors.
 
 
According to an unnamed source close to thesituation who was cited by Reuters—the same one who said candidates havealready been chosen for an attempted board turnover—GSK will wait, however, tosee how HGS progresses in it ongoing efforts to find a buyer in a separateauction process. Depending on how that pans out, GSK will decide its next movein the $2.6 billion hostile takeover bid, including whether to try to replace HGS'sboard.
 
 
Although GSK already has an advantage over any potential"white knight" rival bidders—because the company has partnerships with HGS ontwo key experimental drugs and the two jointly sell Benlysta—some are sayingthat Celgene Corp. is interested in bidding for HGS, based on unnamed sources.
 
Other market watchers, citing different unnamedsources, say Celgene has no such interest and that the story may simply havebeen a rumor planted to encourage GSK to raise its $13-per-share offer.
 


Jeffrey Bouley

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

February 2023 Front Cover

Latest Issue  

• Volume 19 • Issue 2 • February 2023

February 2023

February 2023 Issue